Department of Pharmaceutical Sciences, College of Pharmacy, University of Kentucky, Lexington, Kentucky, United States of America.
PLoS One. 2013 Sep 9;8(9):e73732. doi: 10.1371/journal.pone.0073732. eCollection 2013.
The proteasome is a key regulator of cellular protein homeostasis and is a clinically validated anticancer target. The immunoproteasome, a subtype of proteasome expressed mainly in hematopoietic cells, was initially recognized for its role in antigen presentation during the immune response. Recently, the immunoproteasome has been implicated in several disease conditions including cancer and autoimmune disorders, but many of the factors contributing to these pathological processes remain unknown. In particular, the codon 60 polymorphism of the PSMB9 gene encoding the β1i immunoproteasome catalytic subunit has been investigated in the context of a variety of diseases. Despite this, previous studies have so far reported inconsistent findings regarding the impact of this polymorphism on proteasome activity. Thus, we set out to investigate the impact of the PSMB9 codon 60 polymorphism on the expression and activity of the β1i immunoproteasome subunit in a panel of human cancer cell lines. The β1i-selective fluorogenic substrate Acetyl-Pro-Ala-Leu-7-amino-4-methylcoumarin was used to specifically measure β1i catalytic activity. Our results indicate that the codon 60 Arg/His polymorphism does not significantly alter the expression and activity of β1i among the cell lines tested. Additionally, we also examined the expression of β1i in clinical samples from colon and pancreatic cancer patients. Our immunohistochemical analyses showed that ≈ 70% of clinical colon cancer samples and ≈ 53% of pancreatic cancer samples have detectable β1i expression. Taken together, our results indicate that the β1i subunit of the immunoproteasome is frequently expressed in colon and pancreatic cancers but that the codon 60 genetic variants of β1i display similar catalytic activities and are unlikely to contribute to the significant inter-cell-line and inter-individual variabilities in the immunoproteasome activity.
蛋白酶体是细胞蛋白质稳态的关键调节剂,也是经过临床验证的抗癌靶点。免疫蛋白酶体是在造血细胞中主要表达的蛋白酶体亚型,最初因其在免疫反应期间抗原呈递中的作用而被认识。最近,免疫蛋白酶体已被牵连到几种疾病状况,包括癌症和自身免疫性疾病,但许多导致这些病理过程的因素仍不清楚。特别是,编码 β1i 免疫蛋白酶体催化亚基的 PSMB9 基因的密码子 60 多态性已在各种疾病的背景下进行了研究。尽管如此,迄今为止,先前的研究报告关于该多态性对蛋白酶体活性的影响的结果不一致。因此,我们着手研究 PSMB9 密码子 60 多态性对一系列人类癌细胞系中 β1i 免疫蛋白酶体亚基的表达和活性的影响。使用β1i 选择性荧光底物 Acetyl-Pro-Ala-Leu-7-amino-4-methylcoumarin 特异性测量β1i 催化活性。我们的结果表明,密码子 60 Arg/His 多态性在测试的细胞系中不会显著改变β1i 的表达和活性。此外,我们还检查了来自结肠癌和胰腺癌患者的临床样本中的β1i 表达。我们的免疫组织化学分析表明,约 70%的结肠癌临床样本和约 53%的胰腺癌样本有可检测到的β1i 表达。总的来说,我们的结果表明,免疫蛋白酶体的β1i 亚基在结肠癌和胰腺癌中经常表达,但β1i 的密码子 60 遗传变异显示出相似的催化活性,不太可能导致免疫蛋白酶体活性在细胞系和个体之间存在显著的变异性。